Sage Therapeutics

SAGE

Biotech

Health Care

Pharma

Country

US

Industry

Health Care

Market Cap

Mid Cap

Num. Employees

689

IPO Date

Jul 18, 2014

Create Alert

SAGE

Country

US

Industry

Health Care

Biotech

Health Care

+1

Create Alert

SAGE Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel medicines. The company is headquartered in Cambridge, Massachusetts and currently employs 689 full-time employees. The company went IPO on 2014-07-18. The firm is focused on developing and commercializing brain health medicines. The firm's product, ZULRESSO (brexanolone) CIV injection, is for the treatment of postpartum depression (PPD) in adults. The company has a portfolio of other product candidates with a focus on modulating two central nervous systems (CNS) receptor systems, GABA and NMDA. The company targets diseases and disorders of the brain with three focus areas: depression, neurology and neuropsychiatry. Its other advanced product candidate is zuranolone (SAGE-217), an oral compound being developed for certain affective disorders, including major depressive disorder (MDD) and PPD. Zuranolone is a neuroactive steroid that is a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors. The firm has a portfolio of other compounds that target GABAA receptors, including SAGE-324.